Facebook
X
LinkedIn
ForwardAPP Derm Deep Dive
Advanced Practice Providers and non-dermatologists who see patients in a clinical setting will benefit from understanding the topics presented.
Target Audience
This activity is designed for an audience of physicians, physician associates and nurse practitioners.
Learning Objectives
- Describe the importance of forming differential diagnosis
- Develop ability to properly diagnose through grouping of examination findings, termed categorization
- Organize Power Categories for common dermatologic conditions
- Implement differential diagnostic skills by using Power Categories
- Identify the primary lesions of acne
- Recognize the pathogenesis of acne
- Define the medications used in topical therapy
- Organize oral therapy options for acne
- Identify the side effects of common acne therapies
- Identify the clinical presentation of perioral dermatitis
- Describe the pathogenesis of acne rosacea
- Identify the fundamentals of topical therapy of acne rosacea
- Select oral therapy options for acne rosacea and acne vulgaris variants
- Identify the changes of steroid dermatitis
- Identify fundamental basics of diagnosis for actinic keratosis
- Describe risk factors for actinic keratosis
- Define clinical features of progression from actinic keratosis to squamous cell carcinoma
- Explain treatment options including long term analysis
- Describe Field Cancerization in review of the concept
- Define the basis for the term ‘ECZEMA’
- Identify types of eczematous dermatitis
- Discern etiologic and aggravating factors to atopic dermatitis
- Describe the immune components of atopic dermatitis
- Classify therapy and updated treatments
- Identify features of diagnosis for basal cell carcinoma
- Stratify risk factors for basal cell carcinoma
- Discuss treatment options including long term analysis
- Identify appropriate therapy based on subtype of tumor
- Recognize American Academy of Dermatology basal cell carcinoma treatment guidelines
- Discuss features of common benign growths
- Examine differential diagnosis for common skin conditions
- Describe unusual benign tumors
- Identify Blaschko’s lines presentation and contribution to epidermal nevi
- Determine risk of basal cell carcinoma in nevus sebaceous
- Identify key features in diagnosis of lichen planus
- Interpret scale, Wickham’s striae and color of lesions to aid in diagnosis
- Define potential etiologic agents of lichen planus
- Formulate a differential diagnosis for papulosquamous lesions
- Identify and understand significance of lichen sclerosis et atrophicus
- Identify primary lesion morphology of pityriasis rosea
- Discuss suspected causes of pityriasis rosea
- Expand knowledge of differential diagnosis through utilization of power categories
- Describe therapeutic options of pityriasis rosea
- Recognize clinical presentations for pityriasis lichenoides et varioliformis acuta
- Identify the type of lesions noted in psoriasis and seborrheic dermatitis
- Define the morphologic characteristics of primary lesions in the above diagnostic entities
- Organize the basic treatment parameters as well as some of more advanced therapeutic options
- Relate the associated general medical conditions associated with psoriasis and seborrheic dermatitis
- Describe fundamentals in the basics of diagnosis of squamous cell carcinoma
- Define risk factors for squamous cell carcinoma
- Identify clinical features of progression from actinic keratosis to squamous cell carcinoma
- Discuss treatment options including long term analysis
- Comprehend field cancerization in dermatology
- Identify primary lesion morphology of urticaria
- Describe the pathophysiology of urticaria
- Implement differential diagnosis formulation through utilization of power categories
- Recognize clinical factors which suggest a biopsy is indicated
- Define therapeutic options of urticaria
Commercial Support
There is no commercial support for this activity.
DISCLOSURES | ||
Name | Relationship | Commercial Interest |
Roger T. Moore, MD (planner, faculty) | N/A | Nothing to disclose |
Dorothy Caputo, MA, BSN, RN, President | N/A | Nothing to disclose |
Bernadette Makar, MSN, APRN-BC, NP-C (planner/reviewer) | N/A | Nothing to disclose |
Michele Bielarski, RN (planner/reviewer) | N/A | Nothing to disclose |
AKH Inc Staff and Planners | N/A | Nothing to disclose |
Dermwise Inc. Staff and Planners | N/A | Nothing to disclose |
All of the relevant financial relationships listed for these individuals have been mitigated. | ||
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to [email protected] with your information with "Opt Out" in the subject line.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Dermwise Inc. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 21 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 21 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Associates
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 21 AAPA Category 1 CME credits. Approval is valid until 1/10/2026. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioners
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Dermwise,Inc. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 21 contact hour(s) (which includes 3.0 hour(s) of pharmacology).
Available Credit
- 21.00 AANP
- 21.00 AAPA Category 1 CME
- 21.00 AMA PRA Category 1 Credit™
- 21.00 Attendance